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Introduction
Alterations of the serotoninergic system are well-known
in migraine, however, the other main route of trypto-
phan metabolism, the kynurenine pathway has not yet
been investigated in migraine. Psychiatric comorbidity,
especially depression is highly frequent in migraine
patients, but the exact pathomechanism is not fully
clarified.
Aims
To investigate kynurenine metabolites in migraine
patients, and to assess psychiatric comorbidity.
Methods
The study was approved by the Ethical Committee of
the University of Szeged. 47 migraine patients and
43 healthy controls have been involved, written
informed consent was obtained from every participant.
Headache patients were classified according the IHS cri-
teria. Depression, anxiety, stress, and quality of life were
assessed by validated questionnaires: the Beck Depres-
sion Inventory, the Holmes and Rahe Stress Scale, the
SF-36, and the Spielberger State-Trait Anxiety Inven-
tory. Serum samples have been analyzed by HPLC.
Results
31% of migraine patients presented depressive symp-
toms. Migraine patients had a significantly lower quality
of life, which showed a strong correlation with psychia-
tric comorbidity. Tryptophan levels were significantly
lower in migraineurs than in controls. Serum indolea-
mine 2,3-dioxygenase (IDO) activity, calculated by
kynurenine/tryptophan ratio, was significantly higher in
migraine patients with depressive symptoms, while in
non-depressed patients IDO activity was not statistically
different.
Conclusions
Psychiatric comorbidity, especially depression is highly
prevalent among migraine patients, and contributes to
the worsening of quality of life. The alterations in trypto-
phan-kynurenine metabolism might contribute to patho-
mechanism of migraine and depression comorbidity.
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